

**Form 51-102F3**  
**Material Change Report**

**Item 1            Name and Address of Company**

Biocure Technology Inc. (the “Company”)  
950-1130 West Pender Street  
Vancouver, B.C. V6E 4A4

**Item 2            Date of Material Change**

May 31, 2023

**Item 3            News Release**

A news release was disseminated on June 1, 2023 through the facilities of Stockwatch.

**Item 4            Summary of Material Change**

The Company has completed the previously announced sale of 1,773,879 common shares and 57,954 preferred shares of BiocurePharm Corporation (“BPK”) held by the Company to its President and CEO, Sang Mok Lee (the “Transaction”).

**Item 5            Full Description of Material Change**

The Company has completed the Transaction. The securities sold represent 51% of the shares of BPK currently held by the Company and 46% of the outstanding shares of BPK. As consideration of the BPK shares, Dr. Lee transferred to the Company an aggregate of 27,317,506 common shares of Biocure held by him which shares were cancelled.

As Dr. Lee is a director and officer of the Company, he is a “related party” to the Company within the meaning of Multilateral Instrument 61-101- Protection of Minority Security Holders in Special Transactions (“MI 61-101”). As such, the Transaction constituted a “related party transaction” within the meaning of MI 61-101

Prior to the Transaction, Dr. Lee held 27,317,506 common shares of the Company and 1,000,000 stock options, representing 25% of the issued and outstanding shares. Following the Transaction, Dr. Lee holds no common shares of the Company and retains 1,000,000 stock options, representing less than 1% of the shares on a partially diluted basis.

The Transaction was described in the Information Circular of the Company dated January 13, 2023. The Transaction was approved by the minority shareholders of the Company on February 17, 2023.

**Item 6**            **Reliance on subsection 7.1(2) or (3) of National Instrument 51-102**

This Report is not being filed on a confidential basis in reliance on subsection 7.1(2) or (3) of National Instrument 51-102.

**Item 7**            **Omitted Information**

No information has been omitted on the basis that it is confidential information.

**Item 8**            **Executive Officer**

Konstantin Lichtenwald is knowledgeable about the material change and the Report and may be contacted (604) 609-7146.

**Item 9**            **Date of Report**

June 2, 2023